<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04127721</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0505</org_study_id>
    <secondary_id>NCI-2019-05753</secondary_id>
    <secondary_id>2018-0505</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04127721</nct_id>
  </id_info>
  <brief_title>Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation</brief_title>
  <official_title>Itacitinib to Prevent Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well itacitinib works in preventing graft versus host disease
      in patients with blood disorders undergoing donor stem cell transplantation. A donor
      transplantation uses blood-making cells from a family member or unrelated donor to remove and
      replace abnormal blood cells. Graft versus host disease is a reaction of the donor's immune
      cells against the patient's body. Itacitinib plus standard treatment may help prevent graft
      versus host disease in patients who have received a donor stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To estimate the graft-versus (vs.) host disease-free/relapse free survival (GRFS) rate of
      itacitinib used as prophylaxis to prevent graft versus host disease (GVHD) after allogeneic
      stem cell transplantation (ASCT) at one year.

      SECONDARY OBJECTIVES:

      I. To assess the time to neutrophil and platelet engraftment and compare between matched and
      unmatched donors.

      II. To assess safety of itacitinib as measured by non-relapse mortality (NRM) at day 100.

      III. To assess the toxicity profile associated with this regimen. IV. To assess the incidence
      of acute and chronic GVHD. V. To assess the incidence of disease relapse. VI. To assess the
      incidence of non-relapse mortality. VII. To assess overall survival and progression-free
      survival. VIII. To assess the incidence of withdrawal syndrome in patients with
      myelofibrosis.

      TERTIARY OBJECTIVES (CORRELATIVE STUDIES):

      I. To study immune recovery and cytokines at various time points pre and post-transplant.

      II. To study deoxyribonucleic acid (DNA) damage studies in various cells post-transplant.

      OUTLINE:

      CONDITIONING CHEMOTHERAPY: Patients receive busulfan intravenously (IV) over 3 hours on days
      -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of
      disease progression or unacceptable toxicity.

      ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.

      GVHD PROPHYLAXIS: Patients receive itacitinib orally (PO) once daily (QD) on days -21 to 80.
      Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day
      90. Patients also receive tacrolimus IV then PO twice daily (BID) for 3 months when able, and
      methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched
      unrelated donor).

      After completion of study treatment, patients are followed up at 100 days, 6 months, and 1
      year.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2020</start_date>
  <completion_date type="Anticipated">August 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft versus host disease (GVHD)-free/relapse free survival rate</measure>
    <time_frame>At 1 year</time_frame>
    <description>The proportion of patients who are alive without disease relapse of GVHD at one year will be reported, along with the corresponding 95% confidence interval. Logistic regression will be used to assess the association between success and clinical and treatment covariates of interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>Up to day 42</time_frame>
    <description>Will be calculated from the time of transplant and estimated by the Kaplan-Meier method. Distributions will be compared between patients with matched and mismatched donors via the long-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>Up to day 42</time_frame>
    <description>Will be calculated from the time of transplant and estimated by the Kaplan-Meier method. Distributions will be compared between patients with matched and mismatched donors via the long-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence of non-relapse mortality</measure>
    <time_frame>At day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the toxicity profile associated with this regimen</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the incidence of acute and chronic GVHD.</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease relapse</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be modeled using Cox proportional hazards regression models, considering clinical, demographic, and treatment covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-relapse mortality</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will be modeled using Cox proportional hazards regression models, considering clinical, demographic, and treatment covariates of interest. Will be assessed in a competing risks framework, with similar analyses performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess overall survival and progression-free survival.</measure>
    <time_frame>From day of transplant until day of death, assessed up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of withdrawal syndrome in patients with myelofibrosis</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune recovery and cytokines</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Generalized linear mixed models will be used to assess the association between cytokines over time and treatment and other factors.</description>
  </other_outcome>
  <other_outcome>
    <measure>Deoxyribonucleic acid (DNA) damage studies</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The proportion of patients with DNA damage will be reported, and generalized logistic mixed models may be used to assess the association with similar covariates.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Allogeneic Stem Cell Transplant Recipient</condition>
  <condition>Hematologic and Lymphocytic Disorder</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING CHEMOTHERAPY: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, and fludarabine IV over 1 hour on days -6 to -3 in the absence of disease progression or unacceptable toxicity.
ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo ASCT on day 0.
GVHD PROPHYLAXIS: Patients receive itacitinib PO QD on days -21 to 80. Patients with no evidence of GVHD at day 80 receive a tapered dose of itacitinib until day 90. Patients also receive tacrolimus IV then PO BID for 3 months when able, and methotrexate IV over 30 minutes on days 1, 3, and 6 (day 11 also for patients with a matched unrelated donor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo ASCT</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>INCB 039110</other_name>
    <other_name>INCB-039110</other_name>
    <other_name>INCB039110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Prevention (itacitinib, busulfan, fludarabine, ASCT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky performance status of at least 70

          -  Patients with hematological disorders undergoing ASCT with conditioning regimen of
             timed sequential busulfan and fludarabine

          -  Human leukocyte antigen (HLA)-identical sibling or 8/8 matched unrelated donor
             available

          -  Life expectancy of at least 12 weeks (3 months)

          -  Direct bilirubin not greater than 1 mg/dL

          -  Alanine transaminase (ALT) less than or equal 3 x upper limit of normal range

          -  Serum creatinine less than 1.5 x the upper limit of normal range and creatinine
             clearance greater than 50 ml/min

          -  Diffusing capacity for carbon monoxide (DLCO) 65% of predicted corrected for
             hemoglobin

          -  Left ventricle ejection fraction (LVEF) of at least 50%

          -  Women of childbearing potential must have a negative serum pregnancy test performed
             within 7 days prior to the start of study drug. Post-menopausal women (defined as no
             menses for at least 1 year) and surgically sterilized women are not required to
             undergo a pregnancy test

          -  Subjects (men and women) of childbearing potential must agree to use adequate
             contraception beginning at the signing of the informed consent until at least 30 days
             after the last dose of study drug. The definition of adequate contraception will be
             based on the judgment of the principal investigator or a designated associate

        Exclusion Criteria:

          -  Patients with a comorbidity score &gt; 3. The principal investigator is the final arbiter
             of eligibility and enrollment of patients with comorbidity score &gt; 3 and may permit
             enrollment of these patients on individual basis

               -  Active or clinically significant cardiac disease including:

                    -  Congestive heart failure New York Heart Association (NYHA) &gt; class II

                    -  Active coronary artery disease

                    -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta
                       blockers or digoxin

                    -  Unstable angina (anginal symptoms at rest), new-onset angina within 3 months
                       before transplant, or myocardial infarction within 6 months before
                       transplant

          -  Patients with uncontrolled infections

          -  Patients with active hepatitis B and C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uday R Popat</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uday R. Popat</last_name>
    <phone>713-792-8750</phone>
    <email>upopat@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Uday R. Popat</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Uday R. Popat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

